A novel PROTAC molecule dBET1 alleviates pathogenesis of experimental autoimmune encephalomyelitis in mice by degrading BRD4
International Immunopharmacology · 2024
DOI: 10.1016/j.intimp.2024.112646 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Ziwei Song und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, The Second Affiliated Hospital of Harbin Medical University, Harbin 150001, China; The Key Laboratory of Myocardial Ischemia…. Hauptthemen laut MEDLINE: Encephalomyelitis, Autoimmune, Experimental, Mice, Inbred C57BL, Transcription Factors, Astrocytes. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: Second Affiliated Hospital of Harbin Medical University, Key Laboratory of Myocardial Ischemia, Ministry of Education, Harbin Medical University.
Abstract (Originalsprache)
Neuroinflammation and neurodegeneration are hallmarks of multiple sclerosis (MS). Bromodomain-containing protein 4 (BRD4), a bromodomain and extra-terminal domain (BET) protein family member, is indispensable for the transcription of pro-inflammatory genes. Therefore, inhibiting BRD4 may be a prospective therapeutic approach for modulating the inflammatory response and regulating the course of MS. dBET1, a newly synthesized proteolysis-targeting chimera (PROTAC), exhibits effectively degrades of BRD4. However, the precise effects of dBET1 on MS require further investigation. Therefore, we assessed the effect of dBET1 in experimental autoimmune encephalomyelitis (EAE), a typical MS experimental model. Our findings revealed that BRD4 is mainly expressed in astrocytes and neurons of the spinal cords, and is up-regulated in the spinal cords of EAE mice. The dBET1 attenuated lipopolysaccharide-induced expression of astrocytic pro-inflammatory mediators and inhibited deleterious molecular activity in astrocytes. Correspondingly, dBET1, used in preventive and therapeutic settings, alleviated the behavioral symptoms in EAE mice, as demonstrated by decreased demyelination, alleviated leukocyte infiltration, reduced microglial and astrocyte activation, and diminished inflammatory mediator levels. In addition, dBET1 corrected the imbalance in peripheral T cells and protected blood-brain barrier integrity in EAE mice. The underlying mechanism involved suppressing the phosphoinositide-3-kinase/protein kinase B, mitogen-activated protein kinase /extracellular signal-regulated kinase, and nuclear factor kappa B pathways. In summary, our data strongly suggests that dBET1 is a promising treatment option for MS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, The Second Affiliated Hospital of Harbin Medical University, Harbin 150001, China; The Key Laboratory of Myocardial Ischemia, Chinese Ministry of Education, Harbin 150001, China.
- Department of Neurology, The Second Affiliated Hospital of Harbin Medical University, Harbin 150001, China.
- Department of Neurology, The Second Affiliated Hospital of Harbin Medical University, Harbin 150001, China. Electronic address: wuyun7770@163.com.
Förderung
- Second Affiliated Hospital of Harbin Medical University
- Key Laboratory of Myocardial Ischemia, Ministry of Education
- Harbin Medical University
Zitieren
APA
Song, Z., Li, J., He, Y., Wang, X., Tian, J., & Wu, Y. (2024). A novel PROTAC molecule dBET1 alleviates pathogenesis of experimental autoimmune encephalomyelitis in mice by degrading BRD4. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.112646
Vancouver
Song Z, Li J, He Y, Wang X, Tian J, Wu Y. A novel PROTAC molecule dBET1 alleviates pathogenesis of experimental autoimmune encephalomyelitis in mice by degrading BRD4. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.112646
BibTeX
@article{Song2024,
author = {Song, Ziwei and Li, Jin and He, Yijie and Wang, Xiaokun and Tian, Jianan and Wu, Yun},
title = {A novel PROTAC molecule dBET1 alleviates pathogenesis of experimental autoimmune encephalomyelitis in mice by degrading BRD4},
journal = {International Immunopharmacology},
year = {2024},
doi = {10.1016/j.intimp.2024.112646}
}
EUVIMED